Posted by SLS on October 21, 2013, at 13:31:14
Cariprazine is an investigational antipsychotic with antidepressant properties. It is a DA receptor partial agonist, as is Abilify, but is preferential for D3 receptors. It is D2 antagonism that is most responsible for prolactin release and weight gain. Therefore, cariprazine should be weight-neutral compared to Abilify, and perhaps less apt to produce diabetes.
I'll be first in line to try this drug.
- Scott----------------------------------------------------
"Forest has filed New Drug Applications (NDAs) with the U.S. Food and Drug Administration (FDA) for cariprazine for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. Cariprazine is an orally active and potent dopamine D3-preferring D3 /D2 receptor partial agonist. Cariprazine has a low affinity at other receptor sites such as 5-HT2C, muscarinic, and adrenergic which have been associated with adverse events. Cariprazine is also under development as an adjunctive treatment for MDD and for the treatment of bipolar depression. Cariprazine was discovered by Gedeon Richter Plc and is licensed to Forest Laboratories Inc., in the U.S. and Canada." - Business Wire
--------------------------------------------------
.
Some see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1052699
URL: http://www.dr-bob.org/babble/20130930/msgs/1052699.html